Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes is organized by i3 Health.

Release: May 21, 2020
Expiration: May 20, 2021

Accreitation:
Physicians:
• i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. 
• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this program.

Nursing Continuing Professional Development:
• A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
• Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.

Statement of Need:
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusions. Approximately 30% of patients with MDS progress to acute myeloid leukemia (AML). The estimated annual age-adjusted incidence of MDS in the United States is 3 to 4 cases per 100,000 individuals, with approximately 14,011 new cases per year. Considering the aging population, the incidence of MDS will likely grow in persons older than 60 years of age.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess patient and tumor characteristics that can inform personalized care plans for patients with MDS
• Differentiate emerging data and guideline recommendations on therapeutic approaches for lower- risk, higher-risk, and therapy-related MDS
• Evaluate supportive care strategies that can help patients with MDS achieve their goals of cancer therapy

Faculty:
• David P. Steensma, MD, FACP, Senior Physician, Dana-Farber Cancer Institute
• Reza Nejati, MD, Associate Professor, Department of Pathology, TUHS-Fox Chase Cancer Center
• Ilene Galinsky, BSN, MSN, ANP-C, Nurse Practitioner, Dana-Farber Cancer Institute